Porownywarka

Vilon vs Epithalon side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

VilonEpithalon

Udostępnij porównanie peptydów

Wlasciwosc	Vilon	Epithalon
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Lys-Glu, KE Dipeptide	Epitalon, Epithalone, AGAG
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Available in Russia - Not FDA approved Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Immune enhancement, thymic function, longevity	Longevity, telomere support, anti-aging, sleep
Jak dziala	Vilon is presented as a short Lys-Glu dipeptide with a proposed bioregulatory mechanism. The source links it to hypotheses about cellular entry, nuclear effects, immune-related gene expression, DNA-repair gene expression, and chromatin changes seen in cultured lymphocytes. Those points are described as tentative; the supplied evidence does not establish precise molecular targets or independent validation comparable to an approved medicine.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typowe dawkowanie	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral or sublingual	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Dawkowanie z badań	10-20 mg daily · 10-30 day courses · Oral capsules or sublingual	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typowy czas trwania	10-30 day courses	10-20 day cycles
Podanie	Oral capsules or sublingual	Subcutaneous or intramuscular injection
Timing	Morning With or without food	Before bed With or without food
Poziom dowodów	Przedkliniczne	Badania kliniczne
Mozliwe skutki uboczne	Generally reported as well tolerated (Source wording is broad and does not substitute for systematic human safety data.) Brief injection-site discomfort (Listed by the source despite oral or sublingual administration also being reported.) Breast-cancer caution in mouse models (The source-reported mouse-model warning is retained conservatively; no human risk magnitude is established.) +1 więcej Limited human safety data (The supplied evidence does not provide robust human safety characterization.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 więcej Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Podsumowanie researchu	The source characterizes Vilon research as narrow and largely preclinical. It describes mouse work from Khavinson, Anisimov, and colleagues around 2000, including studies in female CBA mice that reported changes such as increased activity, small lifespan effects, and tumor-related outcomes. The same source stresses major limits: a single research lineage, modest reported effects, limited independent replication, and no registered Western randomized human trial evidence. Human anti-aging or immune-rejuvenation claims therefore remain extrapolations from early animal and laboratory findings.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
Referencje	PubMed Springer +1 więcej ResearchGateA synthetic dipeptide vilon L-Lys-L-Glu inhibits growth of spontaneous tumors and increases life span of mice	PubMed PubMed +2 więcej WikipediaEpitalon Springer
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Vilon

Epithalon

Kategoria

Bioregulatory

Znany tez jako

Lys-Glu, KE Dipeptide

Epitalon, Epithalone, AGAG

Zatwierdzony przez FDA

Nie

Status kliniczny

Available in Russia - Not FDA approved

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Immune enhancement, thymic function, longevity

Longevity, telomere support, anti-aging, sleep

Jak dziala

Vilon is presented as a short Lys-Glu dipeptide with a proposed bioregulatory mechanism. The source links it to hypotheses about cellular entry, nuclear effects, immune-related gene expression, DNA-repair gene expression, and chromatin changes seen in cultured lymphocytes. Those points are described as tentative; the supplied evidence does not establish precise molecular targets or independent validation comparable to an approved medicine.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typowe dawkowanie

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral or sublingual

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Dawkowanie z badań

10-20 mg daily · 10-30 day courses · Oral capsules or sublingual

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typowy czas trwania

10-30 day courses

10-20 day cycles

Podanie

Oral capsules or sublingual

Subcutaneous or intramuscular injection

Timing

Morning

With or without food

Before bed

With or without food

Poziom dowodów

Przedkliniczne

Badania kliniczne

Mozliwe skutki uboczne

Generally reported as well tolerated (Source wording is broad and does not substitute for systematic human safety data.)
Brief injection-site discomfort (Listed by the source despite oral or sublingual administration also being reported.)
Breast-cancer caution in mouse models (The source-reported mouse-model warning is retained conservatively; no human risk magnitude is established.)

+1 więcej

Limited human safety data (The supplied evidence does not provide robust human safety characterization.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 więcej

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Podsumowanie researchu

The source characterizes Vilon research as narrow and largely preclinical. It describes mouse work from Khavinson, Anisimov, and colleagues around 2000, including studies in female CBA mice that reported changes such as increased activity, small lifespan effects, and tumor-related outcomes. The same source stresses major limits: a single research lineage, modest reported effects, limited independent replication, and no registered Western randomized human trial evidence. Human anti-aging or immune-rejuvenation claims therefore remain extrapolations from early animal and laboratory findings.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

Referencje

PubMed Springer

+1 więcej

ResearchGateA synthetic dipeptide vilon L-Lys-L-Glu inhibits growth of spontaneous tumors and increases life span of mice

PubMed PubMed

+2 więcej

WikipediaEpitalon Springer

Pełny profil

Zobacz szczegóły